Nyxoah (NASDAQ:NYXH) Given Buy Rating at HC Wainwright

Nyxoah (NASDAQ:NYXH)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $17.00 price objective on the stock. HC Wainwright’s target price suggests a potential upside of 112.50% from the stock’s previous close.

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $16.00 target price on shares of Nyxoah in a research note on Tuesday, November 5th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $17.00.

Nyxoah Stock Up 1.5 %

NASDAQ NYXH traded up $0.12 on Friday, reaching $8.00. 50,444 shares of the stock traded hands, compared to its average volume of 47,929. Nyxoah has a 12 month low of $4.00 and a 12 month high of $20.00. The firm’s fifty day simple moving average is $8.88 and its 200 day simple moving average is $8.53. The company has a debt-to-equity ratio of 0.21, a quick ratio of 4.95 and a current ratio of 5.28.

Hedge Funds Weigh In On Nyxoah

A hedge fund recently bought a new stake in Nyxoah stock. Kovack Advisors Inc. purchased a new position in shares of Nyxoah S.A. (NASDAQ:NYXH) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 10,000 shares of the company’s stock, valued at approximately $96,000.

Nyxoah Company Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.